Accueil / Tag Archives: Webcast (page 10)

Tag Archives: Webcast

Urovant Sciences Reports 2019 First Fiscal Quarter Financial Results

Tuesday, August 13th 2019 at 8:05pm UTC IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)– Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 first fiscal quarter ended June 30, 2019. Recent Business Highlights Announced the …

Plus »

Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update

Monday, August 12th 2019 at 9:06pm UTC Initiated a Non-IND, IRB-Approved Clinical Study for AXA1957 in adolescent subjects with NAFLD Announced the publication in Frontiers of data describing attenuation of muscle atrophy observed with AXA2678 in short-term muscle disuse study Finished the second quarter with $117.9 million in cash and …

Plus »

Axcella Health Reports Second Quarter 2019 Financial Results and Provides Company Update

Monday, August 12th 2019 at 9:06pm UTC Initiated a Non-IND, IRB-Approved Clinical Study for AXA1957 in adolescent subjects with NAFLD Announced the publication in Frontiers of data describing attenuation of muscle atrophy observed with AXA2678 in short-term muscle disuse study Finished the second quarter with $117.9 million in cash and …

Plus »

Millendo Therapeutics Reports Second Quarter 2019 Operating and Financial Results

Monday, August 12th 2019 at 11:30am UTC  – Livoletide pivotal study in Prader-Willi syndrome (ZEPHYR) on track to report topline results in 1H20 – – Nevanimibe CAH Phase 2b study now enrolling under amended protocol – – New program, MLE-301, beginning preclinical development to enable first-in-human study – ANN ARBOR, …

Plus »

Millendo Therapeutics Reports Second Quarter 2019 Operating and Financial Results

Monday, August 12th 2019 at 11:30am UTC  – Livoletide pivotal study in Prader-Willi syndrome (ZEPHYR) on track to report topline results in 1H20 – – Nevanimibe CAH Phase 2b study now enrolling under amended protocol – – New program, MLE-301, beginning preclinical development to enable first-in-human study – ANN ARBOR, …

Plus »

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

Monday, August 12th 2019 at 9:30am UTC Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, Ohio–(BUSINESS WIRE)– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) …

Plus »

AtriCure Enters Into Definitive Agreement to Acquire SentreHEART

Monday, August 12th 2019 at 9:30am UTC Acquisition Expands Addressable Market Opportunity and Complements Offerings for the Treatment of Atrial Fibrillation Announces Updates to 2019 Outlook Conference Call Monday, August 12th at 8:30am ET MASON, Ohio–(BUSINESS WIRE)– AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) …

Plus »

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors

Tuesday, August 13th 2019 at 11:05am UTC – Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – – Median Progression Free Survival (mPFS) Sustained across All Cohorts – – Additional Phase 1 Results Expected to be Presented at Upcoming Medical Meeting …

Plus »

Deciphera Pharmaceuticals Reports Positive Updated Phase 1 Data for Ripretinib in Gastrointestinal Stromal Tumors

Tuesday, August 13th 2019 at 11:05am UTC – Data from Phase 1 Study Supports Ongoing INTRIGUE Phase 3 Clinical Study in Patients with Second-line GIST – – Median Progression Free Survival (mPFS) Sustained across All Cohorts – – Additional Phase 1 Results Expected to be Presented at Upcoming Medical Meeting …

Plus »
>
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE CHEZ BIOTECH FINANCES
Vous appréciez nos informations ?
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHBzOi8vd3d3LmJpb3RlY2gtZmluYW5jZXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDE1LzA3L1NhdHJhLTIubXA0IiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dmdWxsc2NyZWVuPjwvaWZyYW1lPg==
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
Biotech Finances
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...
S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.

S'inscrire au 15H BIOTECH EXPRESS
Chaque jour à 15H recevez gratuitement les news des biotechs, des medtechs,et des fonds spécialisés. Levées ; partenariats ; nominations ; fusacq ; closing ; milestone...
2019 (C) All rights reserved.

En cochant cette case, j’accepte la Politique de confidentialité de ce site et de recevoir des informations de notre part.